Evotec SE has announced the launch of a new company, Breakpoint Therapeutics GmbH, to discover compounds modulating the DNA repair pathway as a source of potential treatments for cancer. In so doing, it joins a number of enterprises that see DNA damage response as a way of developing drugs for patients who don’t respond to existing treatments.
